Login to Your Account

Hybio cleared by CFDA to move into clinic with its generic liraglutide

By David Ho
Staff Writer

Wednesday, October 11, 2017

HONG KONG – Chinese biotech company Hybio Pharmaceutical Co. recently received approval from the CFDA to conduct clinical trials for its generic version of GLP-1 analogue liraglutide.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription